ArticleHealth science reports2024
Serpentine Supravenous Hyperpigmentation, a Phenomenon Following the Administration of Chemotherapeutic Agents: A Systematic Review.
Article in Health science reports, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Characterization and management of serpentine supravenous reaction: A nine-patient case series.JAAD case reports · 2026Article
- Successful Management and Treatment Rechallenge Following Docetaxel-Induced Serpentine Supravenous Hyperpigmentation With Bullous Features: A Case Report.Clinical case reports · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Serpentine supravenous hyperpigmentation (SSH) is known as a phenomenon occurring during the infusion of chemotherapy agents in the underlying veins. Chemotherapy agents have potential to cause infusion reactions when used systematically. Linear hyperpigmentation and reticular hyperpigmentation are the differential diagnosis for this phenomenon. The aim of the present study was to systematically review the serpentine supravenous dermatitis induced by chemotherapeutic agents. Methods: A comprehensive search was conducted in Scopus, PubMed, Embase, and Web of Science bibliometric databases on February 7, 2023. The search keywords were categorized into two groups: SSH and chemotherapy. Any combination between keywords was used for the systematic search. We included any type of article that evaluated the SSH in cancer patients after the infusion of chemotherapeutic agents, including observational studies with at least one eligible patient based on our criteria, case series, and case reports. Studies that reported SSH in non-cancer patients or caused by any medications other than chemotherapeutic agents were excluded. Results: Twenty-five studies were included based on our inclusion criteria consisting of 26 patients. A total of 13 different cancers were reported in the included studies. Lung cancer was the most reported cancer. Also, the mostly reported region of this dermatitis was forearm which was reported in 13 studies. Docetaxel has been used in a total of 11 articles in this study and has independently induced serpentine supravenous dermatitis in seven studies, which is the mostly reported chemotherapeutic agent resulting into serpentine supravenous dermatitis. Most of these skin lesions were self-limiting and with a normal histopathological finding. Conclusion: SSH is a dermatologic reaction, which mostly occur when there is peripheral venous access for the injection of chemotherapeutic agents. The skin lesion will improve spontaneously and have a benign course with no abnormal histopathological pathological finding.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.